Answers are grounded in this paper and cite their sources.
BACKGROUND: Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the effects of CrM in patients with AD. METHODS: In this single-arm pilot trial, we investigated the feasibility of 20 g/day CrM for 8 weeks in 20 patients with AD. We measured compliance throughout; serum creatine at baseline, 4 weeks, and 8 weeks; and brain total creatine (tCr) and cognition (National Institutes of Health [NIH] Toolbox, Mini-Mental State Examination [MMSE]) at baseline and 8 weeks. DISCUSSION: Our data suggest that CrM supplementation is feasible in AD and provides preliminary evidence for future efficacy and mechanism studies. Trial Registration: ClinicalTrials.gov, NCT05383833, registered on May 20, 2022. Highlights: Creatine monohydrate supplementation was feasible in patients with Alzheimer's disease.Creatine monohydrate was associated with increased brain total creatine.Creatine monohydrate was associated with improvements in cognition.Efficacy of creatine monohydrate in Alzheimer's disease should be studied further.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: